secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-09-11T20:13:35+00:00
Accession:  0001628280-26-061558
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye CFO Sharp resigns, CEO Dhillon becomes principal financial officer; regains Nasdaq compliance
--------------------------------------------------------------------------------

- CFO John P. Sharp resigned Sept. 8, 2026; not due to disagreement with auditors or company.
- CEO Punit Dhillon appointed principal financial and accounting officer effective Sept. 8, 2026; compensation unchanged.
- Master Services Agreement with Lohman & Associates terminated effective Sept. 8, 2026.
- Nasdaq confirmed bid price >=$1.00 for 10 consecutive business days (Aug 24-Sep 4, 2026); compliance regained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026061558/0001628280-26-061558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026061558/skye-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer